Testing adjusted doses of emapalumab and ruxolitinib for HLH
Part of Blood & lymphatic clinical trials.
This trial tests two drugs, emapalumab and ruxolitinib, in people with hemophagocytic lymphohistiocytosis (HLH), a condition where the immune system becomes overactive. The goal is to find the safest and most effective doses of these medications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have at least 5 out of 8 specific signs of HLH (like fever, enlarged spleen, or low blood counts).
- You must be between 1 and 70 years old.
- You cannot have received chemotherapy before for HLH.
- If you can become pregnant, you must use effective birth control during the study and for at least 12 months after the last dose.
- You must be able to give informed consent or have a parent/guardian do it for you.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of five drugs to treat a rare blood cancer called NK/T-cell lymphoma that has triggered an abnormal immune response (hemophagocytic lymphohistiocytosis). The goal is to control both the cancer and the harmful immune reaction.
This study tests a combination of two drugs—zanubrutinib and rituximab—to treat HLH that happens in people with B-cell lymphoma. It aims to see if this treatment is safe and works better.
This trial tests a combination of a targeted drug (ruxolitinib) with a less intense version of standard chemo for adults with Hemophagocytic Lymphohistiocytosis (HLH). It aims to control the overactive immune response while reducing side effects.
This trial tests a modified combination of drugs (liposomal doxorubicin, etoposide, and ruxolitinib, with or without a PD-1 inhibitor) for people with HLH. The goal is to see if it helps control the overactive immune response better than standard care.
This Phase 2 study tests ruxolitinib as a first treatment for primary HLH, a rare, sometimes life-threatening immune overreaction. It may help calm the immune system and improve symptoms by blocking key immune signals.
This trial looks at how people with lymphoma-related hemophagocytic lymphohistiocytosis (HLH) respond to treatment. It aims to better describe expected outcomes and who benefits most, which may help guide future care.
Hear when a new Hemophagocytic Lymphohistiocytosis (HLH) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.